Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach of terlipressin. It remains unclear about whether or not continuous infusion of terlipressin should be considered.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: General Hospital of Shenyang Military Region
• Treatments: Lypressin; Terlipressin

Criteria

Inclusion Criteria:

1. A diagnosis of liver cirrhosis;

2. Child-Pugh B or C;

3. Acute gastroesophageal variceal bleeding;

4. Written informed consents. -

Exclusion Criteria:

1. No liver cirrhosis;

2. Child-Pugh class A;

3. Acute upper gastrointestinal bleeding unrelated to varices;

4. Use of somatostatin or octreotide. -